MedWatch

GN Hearing predicts slow start for OTC market

It’ll take time before the over-the-counter hearing aid market can call itself established – especially considering that consumer appetite is currently low, says GN Hearing CEO Gitte Aabo.

GN Hearing's first product targeting the OTC market in the US is Jabra Enhance Plus, and electronics retailer Best Buy has said it will carry the product in fall | Photo: GN Hearing / PR

This week finally saw the release of the US Food and Drug Administration’s (FDA) rules that many, particularly those within the hearing aid industry, have been waiting for for a long time.

Sales of hearing aids in the US will soon be allowed over the counter, meaning no prescription will be needed. Manufacturers can now also begin targeting products for the upcoming OTC market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs